Genomic Medicine Infrastructure: Reimbursed NGS Panels and Matched-Therapy Rates | Diagnostics Market Intelligence

Description

List of Tables

Japan built a national genomic medicine system with unusual deliberateness. Since 2019, comprehensive genomic profiling panels have been reimbursed under national health insurance; a designated network of core and partner hospitals delivers testing; expert panels interpret results; and every report flows into C-CAT, the national cancer genomic database, creating one of the world's most complete population-scale repositories of tumor genomic data. On paper, the architecture is close to exemplary.

In practice, the system is constrained at precisely the point where data becomes treatment. Only a modest share of tested patients receive a therapy matched to their genomic result. The reasons are structural and mutually reinforcing: the roster of reimbursed drugs for actionable alterations is limited by Japan's drug-approval pipeline, clinical trial matching infrastructure is thin outside major centers, expert-panel capacity is finite, and the patients reaching genomic testing are often too late in their disease course to act on what is found. Meanwhile the policy debate has moved to the next generation of questions - liquid biopsy as a first-line profiling route, whole-genome approaches, earlier testing in the treatment pathway, and how C-CAT's data asset should be opened to industry and research.

This report provides the first integrated map of that system for commercial readers. It reconstructs the policy architecture and the hospital network, profiles each reimbursed panel and its vendor - OncoGuide NCC Oncopanel, FoundationOne CDx, Guardant360 CDx, and the Oncomine Dx Target Test - and examines the expert-panel and matched-therapy machinery in operational detail. It analyzes the matched-therapy bottleneck through its component causes, reviews trial-matching infrastructure including academic programs such as SCRUM-Japan, and sets out the secondary-use rules governing C-CAT data access. Comparative chapters benchmark Japan against the United States, Europe, and China.

The report is written for diagnostics companies and panel vendors operating in or entering Japan, pharmaceutical trial-recruitment and medical affairs teams, investors assessing the genomic medicine value chain, and hospital executives planning genomic programs.

Scope and Coverage: The report covers Japan's reimbursed cancer genomic profiling system: policy architecture, hospital network, approved panels, expert panels, matched-therapy pathways, data infrastructure, and industry access. International benchmarking covers the United States, Europe, and China.

Report Highlights:

Designated hospital network structure and the C-CAT data flow
Profiles of each reimbursed panel: OncoGuide, FoundationOne, Guardant360, Oncomine Dx
Expert-panel operating model and capacity constraints
Matched-therapy bottleneck decomposition: drugs, trials, timing, and geography
Trial-matching infrastructure and the SCRUM-Japan academic program
C-CAT secondary-use rules and industry data-access pathways

Product Code: JPH-044

Table of Content

1. Executive Summary

2. Genomic Medicine Infrastructure: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

Sysmex (JP) - co-developer of OncoGuide NCC Oncopanel with the National Cancer Center; CDx partnerships. Guardant Health (US) - Guardant360 CDx liquid-biopsy panel, approved and reimbursed in Japan. Foundation Medicine/Roche (CH) - FoundationOne CDx tissue and liquid panels reimbursed in Japan since 2019. Thermo Fisher Scientific (US) - Oncomine Dx Target Test, first multi-marker CDx approved in Japan (2017). Illumina (US) - sequencing platform base and TruSight Oncology panel. Qiagen (DE) - therascreen CDx assays and QIAGEN Clinical Insights interpretation. Tempus (US) - xT sequencing platform and data business model reference. BGI Genomics (CN) - NGS panels and sequencing infrastructure in China. Riken Genesis (JP) - laboratory performing NCC Oncopanel and clinical NGS testing. SRL/H.U. Group (JP) - reference-laboratory network processing genomic tests for hospitals. AmoyDx (CN) - Pan Lung Cancer PCR panel approved in Japan (2021), a China-to-Japan CDx entry. MGI Tech (CN) - sequencing instruments supplying Asian laboratories.

Product Code: JPH-044

List of Tables

Table 1. Genomic medicine policy timeline: from expert panels to national designation
Table 2. Core hospital designation requirements and functions
Table 3. Partner hospital network structure and distribution
Table 4. C-CAT establishment, governance, and funding
Table 5. C-CAT data flow from hospital submission to national repository
Table 6. Reimbursed cancer genomic profiling panel inventory
Table 7. OncoGuide NCC Oncopanel System: design, co-development with the National Cancer Center, and reimbursement
Table 8. FoundationOne CDx: approval and reimbursement history in Japan
Table 9. FoundationOne Liquid CDx status and positioning
Table 10. Guardant360 CDx: approval and reimbursement pathway in Japan
Table 11. Oncomine Dx Target Test: role in single-gene-to-panel transition
Table 12. Panel selection criteria in clinical practice
Table 13. Tissue sample requirements, failure rates, and pre-analytics
Table 14. Liquid biopsy sampling logistics for genomic profiling
Table 15. Test ordering workflow and turnaround pathway
Table 16. C-CAT report structure and evidence-tier interpretation
Table 17. Expert panel composition, scheduling, and review process
Table 18. Expert panel recommendation categories and documentation
Table 19. Matched-therapy pathway taxonomy: approved drugs, trials, off-label options
Table 20. Companion drug availability for actionable alterations in Japan
Table 21. Drug lag as a constraint on matched therapy
Table 22. Off-label access mechanisms including patient-proposal healthcare
Table 23. Clinical trial matching infrastructure and tools
Table 24. SCRUM-Japan program structure and achievements
Table 25. Pediatric and AYA genomic oncology programs
Table 26. Rare cancer and cancer-of-unknown-primary applications
Table 27. Timing of testing within the treatment pathway
Table 28. Germline finding handling and genetic counseling capacity
Table 29. NHI reimbursement structure and prices for genomic panels
Table 30. Hospital economics of genomic medicine program operation
Table 31. Genomic medicine coordinator staffing and training framework
Table 32. Regional disparities in genomic testing access
Table 33. Patient consent processes for genomic testing and data submission
Table 34. C-CAT secondary-use rules for academic research
Table 35. C-CAT secondary-use rules for industry access
Table 36. National Cancer Center role in genomic medicine governance
Table 37. Sysmex CDx and panel development partnerships
Table 38. Roche and Foundation Medicine Japan operations
Table 39. Guardant Health Japan structure and strategy
Table 40. Thermo Fisher platform positioning in Japan
Table 41. Pharmaceutical industry use of genomic infrastructure for trial recruitment
Table 42. Matched-therapy rate improvement levers under policy discussion
Table 43. International benchmarking: US genomic profiling coverage models
Table 44. International benchmarking: European national genomic programs
Table 45. International benchmarking: China genomic testing landscape
Table 46. Whole-genome and transcriptome expansion debate
Table 47. Liquid-first profiling strategy debate
Table 48. Quality assurance and proficiency testing for genomic panels
Table 49. Policy roadmap and anticipated system reforms
Table 50. Genomic medicine budget impact under NHI and future pricing reviews

List of Figures

Figure 1. Genomic medicine policy timeline in Japan
Figure 2. Core and partner hospital network map
Figure 3. Data flow schematic from patient sample to C-CAT repository
Figure 4. Hospital designation requirement structure
Figure 5. Reimbursed panel inventory map by vendor
Figure 6. OncoGuide NCC Oncopanel workflow
Figure 7. FoundationOne CDx testing workflow
Figure 8. Guardant360 CDx testing workflow
Figure 9. Panel selection decision tree in clinical practice
Figure 10. Tissue and liquid sampling pathway comparison
Figure 11. Test ordering and turnaround process flow
Figure 12. C-CAT report interpretation tier structure
Figure 13. Expert panel workflow from referral to recommendation
Figure 14. Recommendation category map and downstream actions
Figure 15. Matched-therapy pathway diagram from result to treatment
Figure 16. Matched-therapy funnel from testing to treatment
Figure 17. Drug availability map for actionable alterations in Japan
Figure 18. Drug-lag schematic for matched oncology therapies
Figure 19. Trial matching workflow and tool landscape
Figure 20. SCRUM-Japan network structure
Figure 21. Patient journey from consent to matched treatment
Figure 22. Germline finding handling flow
Figure 23. Testing timing along the treatment pathway
Figure 24. Reimbursement structure diagram for genomic panels
Figure 25. Hospital program economics model structure
Figure 26. Staffing model for genomic medicine programs
Figure 27. Regional access disparity map
Figure 28. Consent process flow for testing and data submission
Figure 29. C-CAT academic secondary-use access flow
Figure 30. C-CAT industry data-access flow
Figure 31. Stakeholder ecosystem map for genomic medicine
Figure 32. Vendor positioning map in Japanese genomic profiling
Figure 33. Pharma trial-recruitment integration with genomic infrastructure
Figure 34. Matched-therapy improvement lever framework
Figure 35. US genomic profiling coverage model comparison
Figure 36. European national genomic program comparison
Figure 37. China genomic testing landscape comparison
Figure 38. Whole-genome expansion debate structure
Figure 39. Liquid-first strategy debate structure
Figure 40. Quality assurance program architecture
Figure 41. Variant interpretation workload and tooling map
Figure 42. Genomic counselor and coordinator workforce map
Figure 43. Patient advocacy and access program landscape
Figure 44. Policy roadmap diagram for next-phase reform
Figure 45. Hospital network referral topology
Figure 46. Data infrastructure architecture of C-CAT
Figure 47. Scenario tree for system evolution
Figure 48. Report methodology and data-source schematic
Figure 49. Budget impact schematic for expanded genomic testing
Figure 50. AI-assisted variant interpretation tool landscape

Genomic Medicine Infrastructure: Reimbursed NGS Panels and Matched-Therapy Rates | Diagnostics Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Genomic Medicine Infrastructure: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures